Endologix wins CE Mark reinstatement for AFX, AFX2, touts 3-year post market Ovation study

This study confirms the ability of the Ovation platform to successfully treat a broad array of patient anatomies with a high rate of treatment success and freedom from secondary intervention through mid-term follow-up. We are pleased to have revealed these impressive results at our scientific symposium this year,” study principal investigator Dr. Dierk Scheinert said in a prepared statement. “The addition of these European results continue to validate the excellent clinical results and durability of the ultra-low profile Ovation platform, further confirming the recently announced 5-year Ovation IDE study results with real-world commercial data.  We would like to thank Dr. Scheinert, Dr. Peeters, and all of the investigators for their participation in this important clinical study and congratulate them for their outstanding results,” CEO McDermott said in a prepared release. The post Endologix wins CE Mark reinstatement for AFX, AFX2, touts 3-year post market Ovation study appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Regulatory/Compliance Vascular Endologix Inc. Source Type: news